Image credit: shutterstock
Harvest Integrated Research Organization (HiRO) has announced the completion of its Series A financing in the tens of millions of US dollars. This round of investment is led by OrbiMed, with the participation from existing shareholder, Fontus Capital.
Proceeds from this funding round will be mainly used to accelerate the development of HiRO's overseas market entry, grow its talent pool, expand its digital clinical research management capabilities, and promote multilateral clinical trials in China and the world.
Founded in September 2020, HiRO is an innovative clinical research organization (CRO). Headquartered in Shanghai, the company currently has offices in Beijing, Taipei, Australia, New Zealand, and the Philippines. Led by a management team with over 20 years of industry experience working in top global CROs, HiRO aims to provide innovative and efficient clinical development services for local biotech companies, bringing their therapies to the global market, and global biotech companies, introducing their products in China.
HiRO acquired Pharmaceutical Solutions ("PharmaSols") in December 2021, a CRO with over 20 years of experience in delivering phase I-IV clinical trials across Australia and New Zealand. Through this acquisition, HiRO makes full use of patient resources in Australia and New Zealand to help clients save time, reduce costs, and generate quality data.
